Reserved Target List Restricted Target List and Target Notices Sample Clauses

Reserved Target List Restricted Target List and Target Notices 
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs

Related to Reserved Target List Restricted Target List and Target Notices

  • Development Schedule The schedule for design and development of the "BASE BUILDING WORK" (as defined below) and the "TENANT IMPROVEMENTS" (as defined below), including, without limitation, the time periods for preparation, delivery, review, and approval of construction documents and performance pursuant to such documents, shall be in accordance with the Development Schedule attached hereto as Schedule A, subject to adjustment as mutually agreed by the parties in writing or as provided in this Work Letter (the "DEVELOPMENT SCHEDULE").

  • Research Plans The Research Plan for the [***] Designated Target is attached as Schedule 2.2.3-1. Subsequent Research Plans agreed upon in accordance with Section 2.4.2.4 will be attached as additional sequentially numbered schedules (Schedule 2.2.3-2, Schedule 2.2.3-3, etc.).

  • Development Milestones Subject to the terms and conditions of this Agreement, no later than [**] following the first occurrence of each event described below (each, a “Development Milestone”), on Product-by-Product basis Moderna shall pay Carisma the non-refundable and non-creditable amounts set forth below for each Product to achieve such event (each, a “Development Milestone Payment”): ​ Development MilestoneDevelopment Milestone Payment (in US$ millions) [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] ​ Moderna shall provide written notice to Carisma of the achievement of each Development Milestone within [**] after such achievement. If a Development Milestone for a Product is achieved without the preceding Development Milestone(s) having been achieved for such Product, then the Development Milestone Payment for such preceding Development Milestone(s) shall be paid by Moderna to Carisma together with ​ ​ the Development Milestone Payment for the Development Milestone that was achieved. For example, if the [**] Development Milestone [**] in the table above is achieved for a Product but the [**] Development Milestone [**] in the table above had not been achieved for such Product, then Moderna would pay the Development Milestone Payment for both such [**] Development Milestone and [**] Development Milestone upon achievement of the [**] Development Milestone. Each of the Development Milestone Payments set forth above shall be payable one time only per Product. If Moderna or its Affiliates or Sublicensees Develops a Product that has achieved at least one Development Milestone and subsequently discontinues Development of such Product and Develops a different Product incorporating or directed to the same combination of Collaboration Targets (whether one Collaboration Target or multiple Collaboration Targets), then Moderna shall be required to pay Development Milestone Payments for such different Product only for Development Milestones that had not been achieved by such discontinued Product.

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Development Plan As defined in Section 3.2(a).

  • Title Type of Work Registration No Registration Date Copyright Claimant Colorado Springs, CO, telephone directory, use through January 2007. Text TX0006336412 4/28/2006 Dex Media, Inc. Colville, WA, and surrounding area telephone directory, use through October 2007. Text TX0006444913 10/6/2006 Dex Media, Inc. Corvallis, CO, and surrounding area, alphabetical listings for Albany and surrounding area, use through Oct. 2007. Text TX0006483516 11/7/2006 Dex Media, Inc. Council Bluffs, IA & surrounding areas telephone directory, June 2007. Text TX0006399774 7/17/2006 Dex Media, Inc. Craig, CO, Meeker, Steamboat Springs telephone directory, use through August 2007. Text TX0006426721 8/30/2006 Dex Media, Inc. Davenport, IA, Bettendorf, Scott County telephone directory, use through October 2007. Text TX0006450386 11/7/2006 Dex Media, Inc. Decorah, IA, Elkader, West Union and surrounding area, telephone directory, use through January 2007. Text TX0006329602 4/27/2006 Dex Media, Inc. Denver, CO, covering the metro area (south) Plus telephone directory, use through December 2007. Text TX0006505993 2/2/2007 Dex Media, Inc. Denver, CO, covering the Metro area, telephone directory, use through December 2007. Text TX0006505955 2/2/2007 Dex Media, Inc. Denver, CO, metro area (east) telephone directory, use through December 2007. Text TX0006507709 2/2/2007 Dex Media, Inc. Denver, CO, metro area (west) telephone directory, use through December 2007. Text TX0006507708 2/2/2007 Dex Media, Inc. Des Moines, IA, and surrounding area, telephone directory, use through November 2007. Text TX0006493357 1/5/2007 Dex Media, Inc. Detroit Lakes, MI, telephone directory, use through 2007. Text TX0006357693 6/15/2006 Dex Media, Inc. Detroit Lakes, MN, and surrounding area, telephone directory, use through May 2006. Text TX0006309112 3/1/2006 Dex Media, Inc. Dex Plus-Twin Cities, MN, Minneapolis and surrounding area/Dex Plus-Twin Cities, St. Paul and surround area, use through April 2007. Text TX0006363132 5/17/2006 Dex Media, Inc. Dickinson, NC, telephone directory, February 2007. Text TX0006351989 4/28/2006 Dex Media, Inc. Dubuque, IA, telephone directory, use through September 2007. Text TX0006435132 10/6/2006 Dex Media, Inc. Durango, CO, Cortez, telephone directory, use through May 2007. Text TX0006357682 6/15/2006 Dex Media, Inc. East Central Minnesota, telephone directory, use through 2007. Text TX0006336347 4/27/2006 Dex Media, Inc. East County, OR, telephone directory, use through February 2007. Text TX0006319866 3/27/2006 Dex Media, Inc. East Tucson, AZ, area telephone directory, use through January 2007. Text TX0006299846 2/23/2006 Dex Media, Inc. East Valley, AZ, telephone directory, use through September 2007. Text TX0006449537 10/27/2006 Dex Media, Inc. East Valley PLUS, and surrounding area, use through September 2007. Text TX0006434775 10/6/2006 Dex Media, Inc. Eastern Montana, telephone directory, use through December 2007. Text TX0006538755 1/5/2007 Dex Media, Inc. Edina, MO, St. Louis Park, telephone directory, use through April 2007. Text TX0006346520 5/16/2006 Dex Media, Inc. Englewood, CO, Littleton, Centennial, Highlands Ranch, South Metro Denver, telephone directory, use through June 2007. Text TX0006399802 7/17/2006 Dex Media, Inc. Estes Park, Allenspark, Glen Haven and surrounding area, use through June 2007. Text TX0006372868 6/13/2006 Dex Media, Inc. Eugene, OR, Springfield, Lane County telephone directory, June 2007. Text TX0006369892 6/13/2006 Dex Media, Inc. Eugene/Springfield plus - use through June 2007. Text TX0006374163 6/13/2006 Dex Media, Inc. Evanston/Demmerer--and surrounding area, telephone directory, use through October 2007. Text TX0006455399 11/7/2006 Dex Media, Inc. Evergreen, CO, telephone directory, use through January 2007. Text TX0006336856 4/28/2006 Dex Media, Inc. Fargo, ND, Moorhead, telephone directory, use through March 2007. Text TX0006336418 4/27/2006 Dex Media, Inc. Faribault, MN, Owatonna telephone directory, use through October 2007. Text TX0006450301 11/7/2006 Dex Media, Inc. Farmington, NM, Aztec, Blanco & others, telephone directory, use through February 2007. Text TX0006337696 4/28/2006 Dex Media, Inc. Fergus Falls, MN, telephone directory, use through September 2007. Text TX0006450380 11/7/2006 Dex Media, Inc. Flagstaff, AZ, and surrounding area, telephone directory, use through May 2007. Text TX0006342725 5/31/2006 Dex Media, Inc. Annex 3 to Guarantee and Collateral Agreement

  • Work Plans Tenant shall prepare and submit to Landlord for approval schematics covering the Tenant Improvements prepared in conformity with the applicable provisions of this Work Letter (the “Draft Schematic Plans”). The Draft Schematic Plans shall contain sufficient information and detail to accurately describe the proposed design to Landlord and such other information as Landlord may reasonably request. Landlord shall notify Tenant in writing within ten (10) business days after receipt of the Draft Schematic Plans whether Landlord approves or objects to the Draft Schematic Plans and of the manner, if any, in which the Draft Schematic Plans are unacceptable. Landlord’s failure to respond within such ten (10) business day period shall be deemed approval by Landlord. If Landlord reasonably objects to the Draft Schematic Plans, then Tenant shall revise the Draft Schematic Plans and cause Landlord’s objections to be remedied in the revised Draft Schematic Plans. Tenant shall then resubmit the revised Draft Schematic Plans to Landlord for approval, such approval not to be unreasonably withheld, conditioned or delayed. Landlord’s approval of or objection to revised Draft Schematic Plans and Tenant’s correction of the same shall be in accordance with this Section until Landlord has approved the Draft Schematic Plans in writing or been deemed to have approved them. The iteration of the Draft Schematic Plans that is approved or deemed approved by Landlord without objection shall be referred to herein as the “Approved Schematic Plans.”

  • Development and Regulatory Milestones With respect to each of the following milestones, Ikaria shall pay BioLineRx the corresponding payment set forth below within [**] days after the achievement by Ikaria, its Affiliates or Licensees of such milestone: MILESTONE PAYMENT

  • Commercialization Plans As soon as practicable after formation of the JCC (following Acucela’s exercise of an Opt-In Right under Section 3.1), the JCC shall prepare and approve the initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation (and, if applicable, any New Formulation or Other Indication Product) in the Territory. The Parties shall use Commercially Reasonable Efforts to ensure that such initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation is consistent with the general Commercialization Plan outline set forth in Exhibit C attached hereto and incorporated herein (the “General Commercialization Plan Outline”). The JCC shall prepare and approve a separate Commercialization Plan for Commercialization of Licensed Product for the Initial Indication in the Initial Formulation in the Territory and for Commercialization of each Other Indication Product and New Formulation (if any) in the Territory, and shall update and amend each Commercialization Plan not less than annually or more frequently as needed to take into account changed circumstances or completion, commencement or cessation of Commercialization activities not contemplated by the then-current Commercialization Plan. Amendments and revisions to the Commercialization Plan shall be reviewed and discussed, in advance, by the JCC, and Otsuka agrees to consider proposals and suggestions made by Acucela regarding amendments and revisions to the Commercialization Plan. Any amendment or revision to the Commercialization Plan that provides for an increase or decrease in the number of FTEs for any Phase 3b Clinical Trials or Post-Approval Studies as compared to the previous version of the Commercialization Plan, or that provides for addition or discontinuation of tasks or activities as compared to the previous version of the Commercialization Plan, or that moves forward the timetable for activities reflected in the Commercialization Plan, shall provide for a reasonable ramp-up or wind-down period, as applicable, to accommodate a smooth and orderly transition of Commercialization activities to the amended or revised Commercialization Plan. Each Commercialization Plan shall identify the goals of Commercialization contemplated thereunder and shall address Commercialization (including Co-Promotion) activities related to the Licensed Product (including, if applicable, any Other Indication Product), including:

  • Development License A non-transferable (except as provided in Section 17.1 (Assignment)), sublicensable (subject to Section 11.2.5 (Voyager Sublicense Rights)), worldwide, non-exclusive, royalty-free license under the Genzyme Technology, Genzyme Collaboration Technology and Genzyme’s interest in the Joint Collaboration Technology to (a) Develop the Split Territory Licensed Products and conduct such Split Territory Licensed Program inside and outside the Voyager Territory for Commercialization of such Split Territory Agreement Products in the Field in the Voyager Territory, and (b) Manufacture the Split Territory Licensed Products inside or outside of the Voyager Territory for the purposes of such Development, in each case (a) and (b) as and to the extent set forth in any Global Development Plan or Voyager Territory Development Plan.

Time is Money Join Law Insider Premium to draft better contracts faster.